ResearcherEnfuego Therapeutics Inc.Active in the last 2 years

Lyla Stanland

Verified by NIH RePORTER profile ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on NIH RePORTER profile ID 16139667. Sources: NIH RePORTER.

Their work

Papers: 0
Trials: 0
Grants: 2
Labs led: 0
Collaborators: 1

Papers, trials and grants by year

2025: 1 grant · 2026: 1 grant

Grants 2

Overcoming Adaptive KRAS Inhibitor Resistance with Ligand-Directed KRAS G12V-panTEAD Chimeras R44CA314597 ↗
Ligand-Directed KRAS G12V Mutant-Specific Therapeutics R44CA284932 ↗

Closest collaborators

The 1 strongest of 1 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Chad V Pecot · 2 shared grants, 2025–2026 · strength 2.33
- Grant Overcoming Adaptive KRAS Inhibitor Resistance with Ligand-Directed KRAS G12V-panTEAD Chimeras R44CA314597 ↗
- Grant Ligand-Directed KRAS G12V Mutant-Specific Therapeutics R44CA284932 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.